Year None20232022202120202019 Apr 12, 2023 Arcutis to Present at Upcoming Investor Conference Apr 07, 2023 Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Apr 05, 2023 Arcutis Announces New Coverage for ZORYVE® (Roflumilast) Cream 0.3% with National and Regional Healt Mar 18, 2023 Arcutis Presents Late-Breaking Data from the INTEGUMENT Phase 3 Trials in Atopic Dermatitis at Ameri Mar 09, 2023 Arcutis to Present New Topical Roflumilast Data Including Late Breaking Atopic Dermatitis Pivotal Tr Mar 03, 2023 Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Feb 28, 2023 Arcutis Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update Feb 21, 2023 Arcutis Submits Topical Roflumilast Foam 0.3% New Drug Application to the FDA for the Treatment of S Feb 08, 2023 Arcutis to Report Fourth Quarter 2022 Financial Results and Participate in Upcoming Investor Confere First page « first Previous page ‹ previous Page 1 Current page 2 Page 3 Next page next › Last page last » Displaying 10 - 18 of 21
